Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 9Thoracic 4Dermatologic 2Sarcoma 1Genitourinary 1Breast 1

Conditions

Recurrence 1Melanoma 1Lung Neoplasms 1Kidney Neoplasms 1Carcinoma, Renal Cell 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Trastuzumab 18Radiosurgery 15Capecitabine 13Lapatinib 11Radiotherapy 9Magnetic Resonance Spectroscopy 9trastuzumab deruxtecan 7Temozolomide 6tucatinib 4pembrolizumab 4paclitaxel-Angiopep-2 conjugate 4eribulin 4Vinorelbine 4Specimen Handling 4Paclitaxel 4Methotrexate 4Cisplatin 4sacituzumab govitecan 3pyrotinib 3abemaciclib 3Radiation 3Fluorodeoxyglucose F18 3pertuzumab 2palbociclib 2neratinib 2durvalumab 2cediranib 2cabazitaxel 2Sodium Chloride 2Observation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Brain Neoplasms × Spermine Synthase × Breast × Clear all
NCT03075072 2024-10-23

Hippocampal Sparing Whole Brain Radiation Versus Stereotactic Radiation in Patients With 5-20 Brain Metastases: A Phase III, Randomized Trial

Dana-Farber Cancer Institute

Phase NA Active not recruiting
196 enrolled
BreastCNSDermatologicGenitourinaryThoracic

Brain Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Kidney Neoplasms, Lung Neoplasms, Melanoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡